The A-List: 2004's Trend-Shaping Series A Financings

Analyzing the venture financings closed by 2004's new crop of biotech, diagnostics, and medical device start-ups reveals today's trends that may shape tomorrow's health care industry. Here we point out eleven 2004 Series A financings that identify and illustrate what's hot.

The return of the health care IPO market in late 2003 certainly buoyed industry spirits, particularly in venture capital and entrepreneurial sectors, although VCs on the whole could be forgiven for not being ecstatic about the valuations their portfolio companies were grabbing. Initial public offerings continued throughout 2004, and while few companies of any stripe were able to pair outstanding valuations with solid post-float performances, as we have pointed out throughout the duration of the window in our Valuation Watch columns, in the end it mattered little to the overall scheme. Public money was returning to younger biotech and medical device firms in levels not seen in a few years. (See, for example, "IPO Step-Ups By Therapeutic Area: Is Your Disease Focus Hot or Not?" START-UP, December 2004 Also see "IPO Step-Ups By Therapeutic Area: Is Your Disease Focus Hot or Not?" - Scrip, 1 December, 2004..)

If it is helpful to analyze the appetites of public investors that determine the characteristics of the current crop of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By 

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

Glenmark Fortifying Branded Play, Shifts Focus To High Margin Products

 

Glenmark signals thrust on high margin products, while exiting tail end brands as part of efforts to emerge as a branded company. In-licensed assets like Brukinsa and Tevimbra are seen as pivotal to driving growth alongside.

China-Originated Assets Lead Global GLP-1 Deals

 
• By 

The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.